Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3594459 | 0.90 | SMN1; SMN2 (0.45) | POLBSMN1; SMN2LMNAHPGDALDH1A1 | |
| SCHEMBL771683 | 0.86 | GAA (0.48) | POLBLMNAHPGDALDH1A1RAB9A | |
| SCHEMBL3594828 | 0.80 | GLA (0.39) | SMN1; SMN2HSD17B10MGAMGAASI | |
| SCHEMBL5360827 | 0.79 | PPM1B (0.51) | PPM1BPTPN1PPP1CCPOLBSMN1; SMN2 | |
| SCHEMBL3596679 | 0.79 | PIK3CD (0.37) | POLBALDH1A1RAB9AGAAEPHX2 | |
| SCHEMBL8178256 | 0.77 | NAAA (0.50) | HPGDALDH1A1FAAHEPHX2TSHR | |
| SCHEMBL1616230 | 0.77 | MGAM (0.45) | POLBLMNAALDH1A1RAB9AMGAM | |
| SCHEMBL2363434 | 0.75 | ALDH1A1 (0.40) | SMN1; SMN2ALDH1A1HSD17B10GAAEPHX2 | |
| SCHEMBL30724425 | 0.75 | PIK3CD (0.34) | POLBSMN1; SMN2HPGDTSHR | |
| SCHEMBL696158 | 0.75 | RECQL (0.41) | SMN1; SMN2ALDH1A1GAAUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11020396-B2 | Pyrimidinone derivatives as Cdc7 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-01 | — | — | US | disclosed |
| US-7741497-B2 | Processes for preparing alkyl 3-(4-tetrahydropyranyl)-3-oxopropanoate compound and 4-acyltetrahydropyrane | UBE INDUSTRIES, LTD. (JP) | 2010-06-22 | — | — | US | disclosed |
| US-20070043107-A1 | Processes for preparing alkyl 3-(4-tetrahydropyranyl)-3-oxopropanoate compound and 4-acyltetrahydropyrane | UBE INDUSTRIES, LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1700852-A1 | PROCESSES FOR PRODUCING ALKYL 3-(4-TETRAHYDROPYRANYL)-3-OXOPROPIONATE COMPOUND AND 4-ACYLTETRAHYDROPYRAN | Ube Industries, Ltd. (JP) | 2006-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043107-A1 | Processes for preparing alkyl 3-(4-tetrahydropyranyl)-3-oxopropanoate compound and 4-acyltetrahydropyrane | DHPS, OXER1, CYP4A11 | PPM1B 4329/4885PTPN1 4368/4885PPP1CC 4533/4885 |
| US-11020396-B2 | Pyrimidinone derivatives as Cdc7 inhibitors | CDC7, CDK7, CDK17 | PPM1B 216/4885PTPN1 2214/4885PPP1CC 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.